Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...
Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ...
Nuvalent seeks FDA approval of neladalkib for TKI-pretreated advanced ALK-positive NSCLC, leveraging ALKOVE-1 results demonstrating activity in extracranial disease and brain metastases. ALKOVE-1 ...
Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain ...
Nuvalent submits NDA to US FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC: Cambridge, Massachusetts Wednesday, April 8, 2026, 13:00 Hrs [IST] Nuvalent, Inc., a ...
Please provide your email address to receive an email when new articles are posted on . Alectinib significantly improved DFS in patients with completely resected ALK-positive NSCLC compared with ...
Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations supports ongoing Phase 2 investigation in earlier lines of treatment "Our development strategy has been anchored ...
Roche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has now secured FDA approval in the post-surgical setting as it continues to test the ...
A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma. This is an ASCO Meeting Abstract ...
Drugs targeting mutations in the anaplastic lymphoma kinase gene (ALK) are already useful in lung cancer, but they may also find a use in the treatment of leukemias. ALK mutations were found in two ...
MADRID -- Disease-free survival (DFS) in resectable ALK-positive non-small cell lung cancer (NSCLC) improved by 76% with adjuvant alectinib (Alecensa) compared with chemotherapy, according to a ...
Alectinib, a potent anaplastic lymphoma kinase (ALK) inhibitor, significantly improved disease-free survival (DFS) at 2 years compared with chemotherapy in patients with completely resected ALK+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results